UNSPSC 51333101: Azaquinzole

This classification denotes an antipsychotic agent with the molecular formula C12H16N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T3H6486135, chemically known as 1,3,4,6,7,11b-hexahydro-2h-pyrazino(2,1-a)isoquinoline but generally known as azaquinzole, which bears US NIH Compound Identifier 179345. European Medicines Agency schedules Azaquinzole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05639MIG. The term AZAQUINZOLE is an International Non-Proprietary Name.

Most nations schedule azaquinzole under HS 29335995 and SITC 51576. As of Q4 2014, AZAQUINZOLE remains the US FDA Preferred Term for this commodity. Azaquinzole bears US NLM identifiers UMLS ID C2346894 and NCI Concept Code C74173. SMILES:.

UNSPSC 51333101 Azaquinzole is a Commodity code, but the recent state and local opportunities on file show little activity directly related to this specific pharmaceutical active ingredient. The three most recent postings tag this code while procuring naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs and pharmacy benefit management (Texas Health and Human Services Commission), and multi-source generic pharmaceuticals and over-the-counter products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). The mismatch between the code's nominal scope and the actual solicitation content suggests that azaquinzole procurement either does not drive significant state and local contracting activity or that issuing bodies are applying the code imprecisely to related pharmaceutical and health product categories.

The three opportunities span different issuing-body types and procurement mechanisms. Seminole County, Florida issued an IFB on June 30, 2026, with a July 26, 2023 response date for naloxone and safe drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually), delivered quarterly to the Seminole County Community Health Building. The Texas Health and Human Services Commission posted a Request for Information on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration, on behalf of the Minnesota Multistate Cooperative Purchasing Alliance, issued an RFP due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026, across Minnesota, Oregon, and participating state and local facilities. The geographic spread includes Florida, Texas, and Minnesota, with the MMCAP award covering multiple states.